The role of the topical nasal decongestant oxymetazoline as a novel therapeutic option for post‐acne erythema: A split‐face, double‐blind, randomized, placebo‐controlled trial

医学 红斑 安慰剂 痤疮 皮肤病科 随机对照试验 羟甲唑啉 随机化 置信区间 麻醉 外科 内科学 肾上腺素能受体 病理 受体 替代医学
作者
Chanudda Washrawirul,Thanaporn Puaratanaarunkon,Yuda Chongpison,Nopadon Noppakun,Pravit Asawanonda,Chanat Kumtornrut
出处
期刊:Journal of Dermatology [Wiley]
卷期号:50 (6): 739-745 被引量:2
标识
DOI:10.1111/1346-8138.16749
摘要

Post-acne erythema (PAE) is one of the most common sequelae of acne inflammation. Unfortunately, the treatment of PAE remains challenging due to limited effective topical treatments. The objectives of this study were to evaluate the efficacy and safety of topical oxymetazoline hydrochloride (OxH) 0.05% solution for PAE. This study was a split-face, participants-and investigators-blinded, randomized, placebo-controlled trial conducted between December 2021 and March 2022 in Bangkok, Thailand. Healthy adults aged from 18 to 45 years with mild to severe PAE, according to the Clinician's Erythema Assessment (CEA), on both sides of the face were eligible. After randomization, each participant applied the OxH to one side of their face and a placebo to the contralateral face twice daily for 12 weeks. The primary outcome was PAE lesion counts. The secondary outcomes were erythema index, clinical response rate at week 12 ("clear," "almost clear," or "at least two-grade improvement" by CEA), and patient satisfaction scores. A total of 30 participants were enrolled. The OxH-treated skin showed a significantly greater mean difference (MD) reduction in PAE lesion counts than the placebo after 8 weeks of treatment (4.30, 95% confidence interval [CI] 1.42-7.18). Similarly, the MD reduction of the erythema index was higher in the OxH-treated skin from the second week (11.82, 95% CI 8.48-15.15). Additionally, the OxH-treated side also achieved a higher clinical response rate after 8 weeks of treatment (40.00% vs. 6.67%; p = 0.002) and rated higher satisfaction than those using the placebo at the end of the study (mean [standard deviation] satisfaction score 8.30 [0.18] vs 7.40 [0.18], P < 0.001). There were no serious adverse events or flares of erythema during the study. In conclusion, our study demonstrated that the topical OxH 0.05% solution was effective, well-tolerated, and safe for reducing PAE without a rebound effect. It could be a choice of PAE management. Trial Registration: Thai Clinical Trials Registry No. TCTR20211207004.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Lazarus_x完成签到,获得积分10
1秒前
1秒前
Charming完成签到,获得积分10
1秒前
Uniibooy完成签到 ,获得积分10
1秒前
Andy完成签到,获得积分10
1秒前
一行白鹭上青天完成签到,获得积分10
1秒前
Dingjiani发布了新的文献求助10
1秒前
chr完成签到,获得积分10
2秒前
新秀完成签到,获得积分10
3秒前
3秒前
整齐百褶裙完成签到 ,获得积分10
3秒前
熊本熊完成签到,获得积分10
3秒前
4秒前
dm11完成签到,获得积分10
4秒前
www完成签到 ,获得积分10
4秒前
一秒的剧情完成签到,获得积分10
4秒前
chr发布了新的文献求助10
5秒前
kin完成签到 ,获得积分10
5秒前
SC完成签到,获得积分10
5秒前
王文茹完成签到,获得积分10
5秒前
gjy完成签到,获得积分10
5秒前
打工是不可能打工的完成签到 ,获得积分10
6秒前
科研通AI2S应助25678987654采纳,获得10
6秒前
Candice应助JudgeGoodwin采纳,获得10
6秒前
lan完成签到,获得积分10
8秒前
可耐的紫夏完成签到,获得积分10
8秒前
槐序十五发布了新的文献求助10
8秒前
9秒前
Ch185完成签到,获得积分10
10秒前
饱满秋完成签到,获得积分10
11秒前
11秒前
鸣蜩阿六完成签到,获得积分10
12秒前
南瓜完成签到,获得积分10
13秒前
tangchao完成签到,获得积分10
14秒前
14秒前
Muller完成签到 ,获得积分10
14秒前
ExtroGod完成签到,获得积分10
14秒前
充电宝应助zhi-pengbao采纳,获得10
16秒前
Promise发布了新的文献求助10
16秒前
爆米花应助jzmupyj采纳,获得10
17秒前
高分求助中
The late Devonian Standard Conodont Zonation 2000
The Lali Section: An Excellent Reference Section for Upper - Devonian in South China 1500
Nickel superalloy market size, share, growth, trends, and forecast 2023-2030 1000
Smart but Scattered: The Revolutionary Executive Skills Approach to Helping Kids Reach Their Potential (第二版) 1000
Mantiden: Faszinierende Lauerjäger Faszinierende Lauerjäger 800
PraxisRatgeber: Mantiden: Faszinierende Lauerjäger 800
A new species of Coccus (Homoptera: Coccoidea) from Malawi 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3244924
求助须知:如何正确求助?哪些是违规求助? 2888537
关于积分的说明 8253767
捐赠科研通 2557026
什么是DOI,文献DOI怎么找? 1385593
科研通“疑难数据库(出版商)”最低求助积分说明 650192
邀请新用户注册赠送积分活动 626369